KEMPHARM INC (KMPH) Stock Price, Forecast & Analysis
NASDAQ:KMPH • US4884452065
KMPH Key Statistics, Chart & Performance
The current stock price of KMPH is 5.81 USD. In the past month the price increased by 7.79%. In the past year, price increased by 10.46%.
KMPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KMPH. When comparing the yearly performance of all stocks, KMPH is one of the better performing stocks in the market, outperforming 90.81% of all stocks.
KMPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KMPH. KMPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KMPH Financial Highlights
Over the last trailing twelve months KMPH reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 64.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
KMPH Forecast & Estimates
9 analysts have analysed KMPH and the average price target is 22.78 USD. This implies a price increase of 292.08% is expected in the next year compared to the current price of 5.81.
For the next year, analysts expect an EPS growth of -143.91% and a revenue growth -59.96% for KMPH
KMPH Ownership
KMPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KMPH
Company Profile
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 24 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The firm also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.
Company Info
KEMPHARM INC
1180 Celebration Blvd Ste 103
Celebration FLORIDA 34747 US
CEO: Travis C. Mickle
Employees: 24
Phone: 13219393416.0
KEMPHARM INC / KMPH FAQ
What does KEMPHARM INC do?
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 24 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The firm also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.
Can you provide the latest stock price for KEMPHARM INC?
The current stock price of KMPH is 5.81 USD. The price decreased by -0.34% in the last trading session.
What is the dividend status of KEMPHARM INC?
KMPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of KMPH stock?
KMPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for KMPH stock?
KEMPHARM INC (KMPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
What is the employee count for KMPH stock?
KEMPHARM INC (KMPH) currently has 24 employees.
Can you provide the market cap for KEMPHARM INC?
KEMPHARM INC (KMPH) has a market capitalization of 200.47M USD. This makes KMPH a Micro Cap stock.